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A B S T R A C T
We report our experience from treating a large number of patients who presented 
to the Emergency Department of our Hospital with ST-elevation acute myocardial 
infarction (AMI) with primary percutaneous coronary intervention (PCI). Of the 196 
patients who presented with ST elevation AMI over a period of 12 months, 100 (51%) 
patients underwent primary PCI. Clinical and angiographic data were collected and 
patients were followed up for 9 months. Technical details of the primary PCI, includ-
ing use of balloon, use of thrombus aspiration catheter, stent implantation, use of 
drug eluting stents, and use of GP IIb/ÉÉÉa inhibitors were recorded and correlated to 
clinical and angiographic patient data. Our results are in keeping with those published 
by other groups performing primary PCI. We demonstrated the importance of time 
interval from onset of symptoms until PCI is started. We found that the use of GP 
IIb/IIIa inhibitors was beneficial and emphasized the predictive value of left ventricu-
lar ejection fraction >50% and the importance of achieving TIMI 3 flow in the AMI 
related artery at the end of the procedure.
I N T R O D U C T I O N
Over the past two decades, cardiologists have witnessed and proved the significance 
of timely opening of the occluded infarct-related coronary artery in patients presenting 
with acute myocardial infarction (AMI). Several recent studies [1-5] have demonstrated 
that the most efficient way to achieve a good result is through percutaneous coronary 
intervention (PCI). The adoption of primary PCI as routine treatment in AMI by most 
large hospitals represents an important advance in the management of patients with 
coronary artery disease. Patients presenting with AMI, who are treated with primary 
PCI show decreased mortality and suffer less adverse cardiac events compared with 
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patients who receive the classical treatment with pharmaco-
logical reperfusion using fibrinolysis [6,7].
In our hospital an interventional team is on-call on a 24-
hour basis and “being a high volume center with experienced 
operators with short response times”, as suggested in the 
European Society of Cardiology guidelines for PCI, an at-
tempt is made to routinely manage patients presenting to the 
emergency room with AMI with primary PCI [7]. Thus, the 
objective of the present study was to report our experience 
and clinical outcome of unselected patients who present to 
the emergency room of our hospital with ST-elevation AMI 
and are treated with primary PCI.
P A T I E N T S  A N D  M E T H O D S
The population of the study included all patients who pre-
sented to our hospital with ST-elevation AMI and underwent 
primary PCI over a 12-month period starting in October 2004 
and ending in September 2005. One hundred and ninety six 
patients presented to the Emergency Department with ST-ele-
vation AMI, and of those, 100 (51%) patients were transferred 
to the catheterization laboratory for coronary angiography and 
primary revascularization. Patients’ clinical and angiographic 
data were retrospectively collected and patients were followed 
up for 9 months. During follow-up, patients were either seen 
in the out-patient clinic upon completion of 9 months or in-
formation was collected via a phone interview if a visit to our 
hospital was not possible.
Technical details of the primary PCI, including use of 
balloon, use of a thrombus aspiration catheter, implantation 
of stents, type of stents implanted (bare metal-BMS vs drug-
eluting stents-DES), use of GP IIb/ÉÉÉa inhibitors etc., were 
left at the discretion of the operator and were recorded and 
correlated with the demographic, clinical and angiographic 
data. All patients received aspirin and clopidogrel prior to 
the procedure.
In general, vascular access was obtained from the right 
femoral artery, and when not feasible, the contralateral 
femoral artery or the right brachial artery was used. A 6F 
diagnostic and subsequently a similar sized guide catheter were 
employed. A total of 5000-10000 units of heparin was used 
during PCI and the activated clotting time was monitored dur-
ing and after the procedure. Post-procedure sheath removal 
was allowed when ACT fell <200 sec. Use of local hemostatic 
devices was left at the discretion of the operator.
S T A T I S T I C A L  A N A L Y S I S
The analyzed dependent variables of our sample were the 
binary (Yes/No) variables of PCI success (TIMI 3 flow at 
the end of the PCI), readmission and death. To improve our 
analysis, a new binary combined variable was constructed as 
a “total success” variable, deducing its data from the origi-
nal dependent variables. In order to investigate the effect of 
any independent variable on the odds of the events, we used 
univariate and multivariate logistic regression models. The 
building of the multivariate models followed a forward pro-
cedure, using the likelihood ratio test. After the modelling 
procedure, the Hosmer-Lemeshow goodness of fit statistics 
was used. A p-value <0.05 was considered significant. The 
Stata™ 8.0 statistical software was used.
R E S U L T S
Table 1 shows the demographic and clinical characteristics 
of our study population. Overall 196 patients presented to the 
TABLE 1. Clinical and Angiographic Characteristics of 100 
Study Patients
Patient characteristic No. of patients
 Age <69 72
 Age 70-79 24
 Age >80 4
 Women 15
 Infarct-related coronary artery 
  Left main 3
  Left anterior descending (LAD) 58
  Circumflex 6
  Right coronary artery (RCA) 33
 EF >50% 46
 EF <50% 54
 TIMI 3 flow at end of PCI 79
 Time from onset of symptoms to PCI<4h 52
 Stents 
  DES 28
  BMS 72
 Number of stents
  0 7
  1 59
  >1 34
 Balloon predilation 83
 Thrombosis aspiration catheter 29
 GP IIb/ÉÉÉa inhibitors 48
  Thrombolysis 19
 Rehospitalization 21
  New PCI 17
  CABG 4
 Total Deaths 10
  In hospital 6
BMS= bare metal stent; CABG= coronary artery bypass grafting; 
DES= drug eluting stent; EF= ejection fraction; GP= glycoprotein; 
PCI= percutaneous coronary intervention
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Emergency Department with ST-elevation AMI over the study 
period. Of these 196 patients, 100 (51%) underwent primary 
PCI. These were 85 male and 15 female patients, of whom 
72 were less than 69 years of age, 24 were between 70 and 79 
years of age and 4 were over 80 years old.
The PCI procedure was considered successful if at the end 
of the procedure a TIMI 3 flow was achieved in the infarct-
related coronary artery [8]. TIMI 3 flow in the infarct artery 
was obtained in 79 (79%) of the 100 patients at the end of the 
procedure. Six (6%) patients died during hospitalization and 
another 4 (4.3%) patients died during the 9-month follow up 
period. Twenty one (22%) patients required rehospitalization 
for a new acute coronary syndrome (ACS), of whom 17 needed 
a second PCI and 4 patients were submitted to coronary artery 
bypass grafting.
The left ventricular ejection fraction (EF) was measured 
routinely by echocardiogram at the Emergency Department. 
Of the 100 patients, 46 (46%) patients were found to have EF 
≥50%, while the remaining 54 (54%) had EF <50%. In 52 
patients primary PCI was performed in less than 4 hours from 
onset of symptoms. Of the 100 patients, 19 were thrombolyzed 
(either with full or half dose thrombolytic) before arriving to 
the catheterization laboratory. Antithrombotic therapy with 
IIb/IIIa inhibitors, eptifibatide and tirofiban being the only 
GP IIb/ÉÉÉa inhibitors available in our hospital, were used in 
48 (48%) patients.
The standard practice in our Institution during primary 
PCI was to treat only the infarct related artery. Stent implanta-
tion was routinely performed at the culprit lesion, however in 
this group, 7 patients did not receive any stent due to unsuc-
cessful PCI, 59 patients received one stent and 34 patients had 
more than one stent implanted. In our hospital drug eluting 
stents (DES) are implanted according to the indications pub-
lished by the European Society of Cardiology guidelines [7], 
hence in this study-group 28 patients received DES. Balloon 
predilation was performed in 83 patients. In 29 patients a 
thrombus aspiration device was used.
Both single-factor and multi-factor logistic regression 
analysis was applied for the statistical analysis. Concerning 
the TIMI 3 flow, univariate analysis showed that the odds 
of achieving TIMI 3 flow after using GP IIb/ÉÉÉa inhibitors 
were 3.48 times higher than if GP IIb/ÉÉÉa inhibitors were not 
used. If the left ventricular ejection fraction was ≥50% at the 
beginning of the PCI, the odds of achieving TIMI 3 flow at 
the end of the procedure were 6.4 times higher for the patient 
than if the EF was <50%.
If the time from the onset of symptoms to PCI was >4 h, 
the odds of achieving TIMI 3 flow at the end of the procedure 
were reduced by 23.4% compared to time from symptoms to 
PCI <4 h. Using death as a single-factor for our statistical 
analysis we found that the presence of TIMI 3 flow of the 
infarct-related artery at the end of PCI reduced the odds of 
death by 10.2% compared to the absence of TIMI 3 flow of the 
infarct-related coronary artery. An increase of the patient’s age 
by 1 year conferred an 11% increase of the odds of death.
D I S C U S S I O N
In this study we report our results and share our experi-
ence from performing primary PCI in a consecutive series of 
patients who presented with ST-elevation AMI to our Institu-
tion. In the “Evagelismos” hospital there are two independent 
cardiology departments which follow different treatment strat-
egies each, for patients with AMI. One Department routinely 
treats all ST-elevation AMI with primary PCI, whereas the 
other Department follows a more conservative strategy by 
referring to the catheterization laboratory for primary PCI 
only the hemodynamically unstable patients, patients with 
extended anterior MIs or those patients who do not respond 
to thrombolysis. This is why only 100 (51%) of the 196 patients 
who presented in the Evagelismos hospital with AMI under-
went primary PCI. The comparison of the strategies applied 
by the two departments is a subject of a different study.
In this study we found that the use of GP IIb/ÉÉÉa inhibitors 
increases the odds of achieving TIMI 3 flow of the infarct-
related coronary artery. Although the use of these agents is 
not formally recommended by the ESC guidelines for PCI in 
this group of patients, there have been other studies reporting 
results from the use of GP IIb/ÉÉÉa inhibitors in agreement 
with our findings [7,10,11]. Probably there is a benefit from 
the use of GP IIb/ÉÉÉa antagonists in primary PCI for patients 
with ST-elevation AMI but this requires further investigation 
with larger and randomized trials.
There have been several studies emphasizing the impor-
tance of baseline LVEF as a predictive variable of mortality 
after primary PCI as well as a determinant of success for pri-
mary PCI [12,13]. In the present study we found that a good 
baseline LVEF at the beginning of PCI increased the odds of 
achieving TIMI 3 flow at the end of the procedure.
The importance of time from onset of symptoms to PCI is 
pointed out in every report of primary PCI and it is clear that 
the patient should be transferred to the catheterization labora-
tory as soon as possible. In the current study we found that if 
the time from onset of symptoms to primary PCI exceeded 
4 hours, the odds of achieving TIMI 3 flow were severely 
reduced compared to patients who were transferred to the 
catheterization laboratory within the first 4 hours.
The importance of time elapsing from the onset of symp-
toms to the application of the interventional procedure was re-
cently shown in a most recent meta-analysis of 22 randomized 
trials comparing primary percutaneous coronary interventions 
(PCI) with fibrinolysis [9]. The authors stress the importance 
of avoiding any delay in the interventional treatment, because 
the longer the delay the higher the mortality. Nevertheless, 
this meta-analysis showed that ‘Primary PCI proved superior 
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to fibrinolysis, regardless of treatment delay’.
Age is an independent predictor of cardiac death after 
primary PCI. This finding has been reported in several studies 
and it was true for our patient cohort as well [2,14]. Another 
strong independent predictor of mortality after primary PCI 
is TIMI 3 flow of the infarct-related artery at the end of the 
procedure [12], which was also true for our study-group.
C O N C L U S I O N S
The results from this relatively small observational study 
are in keeping with the results published by other groups 
performing primary PCI. Transferring the patients to the 
catheterization laboratory as soon as possible is of paramount 
importance in achieving TIMI 3 flow. The use of GP IIb/ÉÉÉa 
inhibitors before the initiation or during the performance of 
primary PCI increases the odds of achieving TIMI 3 flow. 
Left ventricular EF >50% is a factor that predicts success of 
the procedure and good long-term results. TIMI 3 flow at the 
end of the procedure in the infarct-related coronary artery is 
a powerful predictor for good long-term results.
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